Newswire (Published: Wednesday, October 16, 2019, Received: Wednesday, October 16, 2019, 6:07:25 PM CDT)

Word Count: 421

2019 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting out of York, United Kingdom, by NewsRx editors, research stated, “Prostate cancers have a justified reputation as one of the most heterogeneous human tumours. Indeed, there are some who consider that advanced and castration-resistant prostate cancers are incurable, as a direct result of this heterogeneity.”

Our news journalists obtained a quote from the research from the University of York, “However, tumor heterogeneity can be defined in different ways. To a clinician, prostate cancer is a number of different diseases, the treatments for which remain equally heterogeneous and uncertain. To the pathologist, the histopathological appearances of the tumours are notoriously heterogeneous. Indeed, the genius of Donald Gleason in the 1960s was to devise a classification system designed to take into account the heterogeneity of the tumours both individually and in the whole prostate context. To the cell biologist, a prostate tumor consists of multiple epithelial cell types, inter-mingled with various fibroblasts, neuroendocrine cells, endothelial cells, macrophages and lymphocytes, all of which interact to influence treatment responses in a patient-specific manner. Finally, genetic analyses of prostate cancers have been compromised by the variable gene rearrangements and paucity of activating mutations observed, even in large numbers of patient tumours with consistent clinical diagnoses and/or outcomes. Research into familial susceptibility has even generated the least tractable outcome of such studies: the genetic loci are of low penetrance and are of course heterogeneous.”

According to the news editors, the research concluded: “By fractionating the tumor (and patient-matched non-malignant tissues) heterogeneity can be resolved, revealing homogeneous markers of patient outcomes.”

For more information on this research see: Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment. Advances In Experimental Medicine and Biology, 2019;1164():207-224.

Our news journalists report that additional information may be obtained by contacting N.J. Maitland, Cancer Research Unit, Dept. of Biology, University of York, York, UK. Additional authors for this research include F.M. Frame, J.K. Rane, H.H. Erb, J.R. Packer, L.K. Archer and D. Pellacani.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/978-3-030-22254-3_16. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of York

Places

Northern Europe
United Kingdom
Europe
England
York

Subjects

Science and Technology
      Scientific Research
            Medical Research
                  Clinical Outcomes
      Sciences
            Natural Sciences
                  Biology
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
                  Clinical Outcomes